ACCORD, ADVANCE & VADT. Now what do I do in my practice?

Size: px
Start display at page:

Download "ACCORD, ADVANCE & VADT. Now what do I do in my practice?"

Transcription

1 ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com

2 Presenter Disclosure Information Richard M. Bergenstal, MD I have participated in clinical research, served on a scientific advisory board and/or consulted with: Eli Lilly Novo Nordisk Sanofi-Aventis MannKind I have inherited Merck stock Roche LifeScan / J&J Abbott Bayer Medtronic Intuity Valeritas Amylin Merck Pfizer ResMed Novartis I have received no personal compensation for any of these activities and all contracts are with the non-profit Park Nicollet Institute for Research & Education Current officer of the American Diabetes Association

3 In the News: February 7, 2008 The ACCORD Trial and Diabetes Care Diabetes Study Halted After Deaths Deaths Prompt Halt in Diabetes Study: Study of Intensive Treatment of Diabetes Curtailed Because of Increased Death Rates International Diabetes Center Park Nicollet

4 ACCORD: 3 Medical Strategy Questions Glycemia (open-label trial) (n=10,251) Intensive treatment (A1C<6.0%) vs Standard treatment (A1C 7.0%-7.9%) BP (open-label trial) (n=4,733) Intensive treatment (SBP <120 mmhg) vs Standard treatment (SBP <140 mmhg) Lipids (double-blind trial) (n=5,518) Fibrate to increase HDL-C and lower TG + statin to lower LDL-C vs Placebo + Statin to lower LDL-C (ACCORD Study Group, Am J Cardiol 2007;99[suppl]:21i-33i)

5 ACCORD Double 2 x 2 Factorial Design ADVANCE VADT Intensive (SBP<120) BP Standard (SBP<140) Lipid stain + fibrate vs statin + placebo Group A Group B Intensive Glycemic Treatment (A1C<6%) * Standard Glycemic Treatment (A1C 7-7.9%) * 2362* 2371* 2753* 2765* 10,251 *Primary analyses compare marginals for main effects (ACCORD Study Group, Am J Cardiol 2007;99[suppl]:21i-33i)

6 Comparison of Recent Glycemia Trials ACCORD, ADVANCE and VADT Characteristic ACCORD ADVANCE VADT N 10,251 11,140 1,791 Mean Age Duration of T2DM 10 yr 8 yr 11.5 yr History of CVD 35% 32% 40% BMI Baseline A1C 8.3% 7.5% 9.4% ACCORD Study Group. N Engl J Med. 2008;358: ADVANCE Collaborative Group. N Engl J Med 358: , Duckworth W for VADT. N Engl J Med 2009;360:129-39

7 Comparison of Recent Glycemia Trials ACCORD, ADVANCE and VADT Characteristic ACCORD ADVANCE VADT N 10,251 11,140 1,791 Mean Age Duration of T2DM 10 yr 8 yr 11.5 yr History of CVD 35% 32% 40% BMI Baseline A1C 8.3% 7.5% 9.4% A1C Achieved 6.4% vs. 7.5% 6.5% vs. 7.3% 6.9% vs. 8.4% RRR CVD Events 0.90 ( ) 0.94 ( ) 0.88 ( ) RRR Mortality 1.22 ( )* 0.93 ( ) 1.07 ( ) ACCORD Study Group. N Engl J Med. 2008;358: ADVANCE Collaborative Group. N Engl J Med 358: , Duckworth W for VADT. N Engl J Med 2009;360:129-39

8 Impact of Intensive Therapy for Diabetes: Summary of Major Clinical Trials Study Microvascular CVD Mortality UKPDS DCCT/EDIC ACCORD Pending ADVANCE VADT Initial Trial International Diabetes Center 2008 UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352: Holman RR. N Engl J Med Oct 9;359(15): DCCT Research Group. N Engl J Med 329; , 1993 Nathan DM, et al. N Engl J Med. 2005;353: Gerstein HC, et al. N Engl J Med. 2008;358: Patel A, et al. N Engl J Med. 2008;358: Duckworth W et al N Engl J Med 2009;360: Long Term Follow-up

9 Intensive Glycemic Control in Diabetes: Implications of ACCORD, ADVANCE and VADT Skyler JS. Diabetes Care. 2009;32(1):187-92

10 Intensive Glycemic Control in Diabetes: Implications of ACCORD, ADVANCE and VADT Glycemic targets Lowering A1C to < 7% significantly lowers the risk of microvascular complications in both type 1 and type 2 diabetes Controlled trials of more intensive glycemic control have not demonstrated a reduction in CVD risk Long-term follow-up suggests that A1C < 7% soon after diagnosis is associated with a reduction in CVD risk years later Until more evidence becomes available, the general A1C target of < 7% is reasonable For selected patients lower or higher A1C targets may be appropriate Skyler JS. Diabetes Care. 2009;32(1): Also published in Circulation and American College of Cardiology

11 Post ADA ACCORD, ADVANCE, VADT I told you glucose control was not important New A1C goal should be <8% - no make that <9% I am sure it was the severe hypoglycemia that killed people I am sure it was silent hypoglycemia coupled with autonomic n. I am sure it was the weight gain that killed people I am sure it was how rapidly the A1C was lowered that killed people Those with diabetes of long duration & known heart disease died Cardiologists were right its all about lipids and blood pressure Time to rewrite guidelines and treatment algorithms ---

12 1. Meta analysis 2. More detailed secondary analyses of ACCORD and VADT data

13 A Broader View of CVD and Diabetes Implications of ACCORD, ADVANCE and VADT A few observation and much reasoning lead to error. Many observations and a little reasoning to truth Alexis Carrel

14 Prevention of CVD Thru Glycemic Control CVD Events and Mortality Risk Mannucci E et al. Nutr Metab Cardiovasc Dis epub ahead of print 8 May 2009

15 Ray et al Lancet May 2009 Meta analysis of RCT s: CVD & Death in DM Non- fatal MI All CHD events

16 Ray et al Lancet May 2009 Stroke Meta analysis of RCT s: CVD & Death in DM All Cause Mortality

17 The ACCORD and ADVANCE Glycemic Control Intensive vs Standard A1C (%) A1C (%) Standard therapy Intensive therapy Time (yrs) Standard control Intensive control Follow-up (months) ACCORD Study Group. N Engl J Med. 2008;358: A1C 7.5% 6.4% A1C 7.0% 6.4%

18 INT vs STD strategy Post-Rz Differences Lower A1C Achieved median 6.4% vs 7.5% Greater use of medications: More multiple oral meds More insulin More consequences of therapy: Severe hypoglycemia Weight gain More SAEs 11% vs 2% on 4-5 oral classes 77% vs 55% on insulin 10.5% vs 3.5% w/ hypoglycemia event requiring medical assistance 28% vs 14% >10 kg gain 2.2% vs 1.6% w non-hypo SAE (NEJM 358:2545, 2008)

19 Can we predict what baseline characteristics increase risk of death? DEMOGRAPHICS MEDICAL HISTORY MEDICATIONS LAB TESTS Age Race/ethnicity Gender Lives alone Clinical network BMI Waist circumference Education Year of randomization Prior CVD event Prior HF DM duration Hx neuropathy Peripheral Neuropathy (MNSI) Retinal laser/surgery Visual acuity Smoking Depression Blood Pressure ECG (MI, QT) SU Metformin TZD Any insulin HCTZ ACE inhibitors Beta blockers CCB Fibrates Statins Aspirin Antidepressants A1C LDL HDL TG Serum Cr GFR (MDRD) Alb/Cr urine

20 Can we predict what baseline characteristics increase risk of death? DEMOGRAPHICS MEDICAL HISTORY MEDICATIONS LAB TESTS Age Race/ethnicity Gender Lives alone Clinical network BMI Waist circumference Education Year of randomization Prior CVD event Prior HF DM duration Hx neuropathy Peripheral Neuropathy (MNSI) Retinal laser/surgery Visual acuity Smoking Depression Blood Pressure ECG (MI, QT) SU Metformin TZD Any insulin HCTZ ACE inhibitors Beta blockers CCB Fibrates Statins Aspirin Antidepressants A1C LDL HDL TG Serum Cr GFR (MDRD) Alb/Cr urine

21 Risk of Death (all-cause) in INT vs. STD Subgroups w/ significant interactions Baseline Subgroup % Deaths (N) STD % Deaths (N) INT INT vs STD Hazard Ratio Interaction P-Value Hba1c < % (1022) 7.5 to % (2200) % (1887) Self-report Hx Neuropathy 4.83% (1036) 4.18% (2226) 6.14% (1857) Yes 4.11% (1410) 7.84% (1327) No 3.84% (3646) 4.10% (3708) Aspirin Use Yes 3.83% (2771) 5.73% (2808) No 4.12% (2352) 4.14% (2320) INT Better STD Better

22 Marginal Significance BMI (interaction p = 0.07) Anti-depressants (interaction p=0.08) Expected, But No Interaction with Treatment Age Prior history of CVD Diabetes Duration

23 Severe Hypoglycemia

24 Severe Hypoglycemia Rates in INT & STD Groups INT intensive STD standard Pts w hypoglycemia events (%) Participants With Hypoglycemic Events (%) Years

25 Persons more or less likely to have severe hypoglycemic event (multivariate analysis) Albumin:creatinine >300: HR 1.74 (95% CI: ) African American: HR 1.43 (95% CI: ) Women: HR 1.21 (95% CI: ) Every 1 yr increase in age: HR 1.03 (95% CI: 1.02, 1.05) BMI > 30: HR 0.65 (95% CI: )

26 Self-reported Antecedents to Hypoglycemia Events Reason % (n=875 events) Delayed/missed meal or ate fewer carbohydrates 58% (510) None 17% (148) Took incorrect dose of glucose lowering medication 9% (82) Cognitive decline 8% (70) Intercurrent illness 5% (44) Ingested alcohol 3% (26) Recent weight loss 3% (29) Started or increase of other medication 3% (28)

27 Risk of Hypoglycemia by Study Group and Average Updated A1C Incidence Per 100 Person Years Intensive INT Standard STD HR for hypoglycemia by each 1% higher updated average A1C: Intensive = 1.15 Standard = 1.76 Higher A1C assoc w/ higher hypoglycemic rates within both groups Updated Average A1C (Quintiles)

28 The ACCORD and ADVANCE Glycemic Control Intensive vs Standard A1C (%) A1C (%) Standard therapy Intensive therapy Time (yrs) Standard control Intensive control Follow-up (months) ACCORD Study Group. N Engl J Med. 2008;358: A1C 7.5% 6.4% A1C 7.0% 6.4%

29 Hypoglycemia Rate Of A1C Change From BL To 4 Months Incidence Per 100 Person Years INT STD HR for hypoglycemia by initial 4-month decrease of an additional percentage point in A1C: Intensive = 0.86 Standard = 0.72 Greater reduction in A1C assoc with lower hypoglycemia rates Baseline A1C Minus Month 4 A1C (Quintiles)

30 No severe hypoglycemia At least one severe hypoglycemia event HR (Hypo vs no Hypo) (95% CI) Mortality by Study Group and Hypoglycemia Occurrence STD (n=175 w/ events) 1.0% / year 180 deaths 17,516 PYs 4.9% / year 17 deaths 345 PYs 2.87 ( ) INT (n=528 w/ events) 1.3% / year 220 deaths 17, 031 PYs 2.8% / year 34 deaths 1,208 PYs 1.28 ( ) Mortality rate higher in those w hypoglycemia regardless of treatment group HR INT vs STD (95% CI) 1.24 ( ) 0.55 ( ) In those w hypoglycemia, mortality rate lower in INT than STD group PY = Person Years

31 Etiologic Fraction of Deaths Possibly Due to Severe Hypoglycemia Intensive Group Etiologic Fraction: 3.4% X Number of deaths: 254 = Number of deaths potentially attributable to hypoglycemia: 9 Standard Group Etiologic Fraction: 5.4% X Number of deaths: 197 = Number of deaths potentially attributable to hypoglycemia: 11

32 Association of Average A1C with Mortality by Tx Strategy Did the Intensive Patients who died have lower A1C s? Hazard Ratio for 1% higher average updated A1C (95% CI), w group assignment added to other covariates: INT strategy 1.66 (1.46, 1.89) p= STD strategy 1.14 (0.95, 1.38) Interaction between INT and STD: p=0.17 p= Relationships between average A1C and mortality differed between treatment strategies

33 Risk of Death over Range of Ave. A1C Smoothed spline plots with 95% confidence intervals, adjusted for all covariates Steady increase of risk from 6% to 9% A1C in INT strategy Log HR of Mortality Relative to 6% A1C INT STD Excess risk with Average INT vs STD A1Cabove A1C 7%

34 Rates of Death During Treatment over a Range of 1-year Change in A1C Excess risk with INT vs STD strategy occurred when INT participants failed to reduce A1C in year 1 Death rates per year INT STD 0.0 A1C decline 0.5 from 1.0 baseline over months 2.0 (%)

35 ACCORD Conclusions: Main Results In people with longstanding T2DM and either CVD or additional CV risk factors, over average 3.5 years A strategy using currently available therapies to target near-normal A1C levels, compared to a more conventional strategy Increased mortality Did not reduce a composite of major CVD events (primary outcome) (NEJM 358:2545, 2008)

36 ACCORD Conclusions: Subgroups and Hypoglycemia Excess mortality from INT vs STD consistent across numerous pre-specified and ad-hoc BL subgroups Regardless of treatment assignment: Hypoglycemia risk is higher in women, African Americans, those w/ renal complications Hypoglycemia event preceded by missed or nontypical meals Severe hypoglycemia is associated with a higher risk of mortality Although hypoglycemia was higher in INT than STD groups, there is no evidence that the hypoglycemia accounted for the higher mortality in INT

37 ACCORD Conclusions: Achieved A1C Higher risk of death associated with higher average updated A1C, esp. in INT Lower achieved A1C not associated with hypoglycemia events nor with mortality: Excess risk of death in INT group occurred in those whose average achieved A1C was higher than 7% More rapid reduction of A1C not assoc with higher risk of death in INT group Excess risk in INT vs STD occurred when INT participants failed to reduce A1C in year 1 Results suggest that, using an intensive strategy: Some with T2DM can safely achieve A1C levels below 7% Others who do not readily reduce A1C may be at risk if they persist with this strategy

38 ACCORD Double 2 x 2 Factorial Design Intensive (SBP<120) BP Standard (SBP<140) Lipid stain + fibrate vs statin + placebo Group A Group B Intensive Glycemic Treatment (A1C<6%) * Standard Glycemic Treatment (A1C 7-7.9%) * 2362* 2371* 2753* 2765* 10,251 *Primary analyses compare marginals for main effects (ACCORD Study Group, Am J Cardiol 2007;99[suppl]:21i-33i)

39 After Statin therapy.what? 60 yr old man Post-MI x 3 yrs Hypertension- treated BMI 29 HbA1c 7.0% TC 250 LDL 165 TG 250 HDL 35 Non HDL mg simvastatin HbA1c 7.0% TC 170 LDL 95 TG 200 HDL 35 Non HDL 135

40 Trial N Mean SBP < intense Mean SBP > intense CVD Risk Reduction SHEP % Syst-EUR % HOT 1, % UKPDS 1, % ABCD No CVD ADVANCE 11, % mortality Cushman, et al. Am J Cardiol 2007;99[suppl]:44i 55i; Patel, et al. Lancet. 2007;370:

41 Achieved Systolic Pressures Means +/- 95% Confidence Intervals Mean # Meds: Mean # Meds: Mean SBP (mmhg) Years Post-Randomization Intensive Standard

42 ACCORD SBP ADV UKPDS UK Prospective Diabetes Study

43 Current BP target in diabetes <130/80 mmhg If the ACCORD BP trial demonstrates a reduction in major CVD outcomes: Recommended SBP goal in DM may be <120 mm Hg If ACCORD does not show CVD benefits for the lower BP goal, guidelines may be changed to reflect the evidence from ADVANCE supporting a higher goal (like systolic135 mmhg).

A Fork in the Road: Navigating Through New Terrain

A Fork in the Road: Navigating Through New Terrain A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

Update on CVD and Microvascular Complications in T2D

Update on CVD and Microvascular Complications in T2D Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Microvascular Complications in Diabetes:

Microvascular Complications in Diabetes: Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History

More information

Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM

Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes

More information

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy? Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists

More information

Slide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now

Slide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for

More information

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Diabetes Mellitus: Implications of New Clinical Trials and New Medications Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October

More information

Diabete: terapia nei pazienti a rischio cardiovascolare

Diabete: terapia nei pazienti a rischio cardiovascolare Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population

More information

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:

More information

The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections

The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections 8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Misperceptions still exist that cardiovascular disease is not a real problem for women. Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Glucose Control and Prevention of Cardiovascular Disease

Glucose Control and Prevention of Cardiovascular Disease Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial?

1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial? Jeff D. Williamson, MD, MHS Chief, Geriatric Medicine Sticht Center on Aging 1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial? 2. Are

More information

Glycemic control a matter of life and death

Glycemic control a matter of life and death Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)

More information

How to Reduce CVD Complications in Diabetes?

How to Reduce CVD Complications in Diabetes? How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year

More information

The ABCs (A1C, BP and Cholesterol) of Diabetes

The ABCs (A1C, BP and Cholesterol) of Diabetes The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department

More information

Complications of Diabetes: Screening and Prevention

Complications of Diabetes: Screening and Prevention Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy

More information

Glucose and CV disease

Glucose and CV disease Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,

More information

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Cardiovascular Management of a Patient with Diabetes

Cardiovascular Management of a Patient with Diabetes Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Causes of death in Diabetes

Causes of death in Diabetes Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Current Updates & Challenges In Managing Diabetes in CVD

Current Updates & Challenges In Managing Diabetes in CVD Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

Treating Hypertension in 2018: What Makes the Most Sense Today?

Treating Hypertension in 2018: What Makes the Most Sense Today? Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or

More information

Management of Diabetes Mellitus: A Primary Care Perspective

Management of Diabetes Mellitus: A Primary Care Perspective Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening

More information

Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD

Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD International Diabetes Center and Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com

More information

Macrovascular Disease in Diabetes

Macrovascular Disease in Diabetes Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based

More information

Aggressive Lipid Management for Diabetes

Aggressive Lipid Management for Diabetes Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics

More information

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:

More information

Prevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine

Prevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine Prevention of complications: are we winning or losing the battle Naveed Sattar Professor of Metabolic Medicine Duality of Interest Declaration Consultant or speaker for: Amgen, AstraZeneca, Boehringer

More information

Management of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test

Management of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening

More information

Preventing Serious Health Consequences of Type 2 Diabetes

Preventing Serious Health Consequences of Type 2 Diabetes Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial 1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.

More information

Update on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH

Update on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH Update on Diabetes Why it s Not Just About Glucose Lowering Any More Ketan Dhatariya Consultant in Diabetes NNUH The Story So Far.. DCCT Retinopathy Neuropathy Nephropathy Intensive glucose control in

More information

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

T2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets

T2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Du gusts is megl che one. Edoardo Mannucci

Du gusts is megl che one. Edoardo Mannucci Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli

More information

CURRENT CONTROVERSIES IN DIABETES CARE

CURRENT CONTROVERSIES IN DIABETES CARE CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Glucose Control: Does it lower CV risk?

Glucose Control: Does it lower CV risk? Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,

More information

Evidence-Based Glucose Management in Type 2 Diabetes

Evidence-Based Glucose Management in Type 2 Diabetes Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine

More information

1/28/2014. The Metabolic Syndrome: Early History. Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease

1/28/2014. The Metabolic Syndrome: Early History. Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease : Early Diagnosis and Treatment to Prevent Cardiovascular Disease Henry N. Ginsberg, M.D. Irving Professor of Medicine Columbia University College of Physicans and Surgeons The Metabolic Syndrome: Early

More information

Management of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas

Management of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support

More information

The New Hypertension Guidelines

The New Hypertension Guidelines The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts

More information

Diabetes Treatment Update

Diabetes Treatment Update Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers

More information

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria 1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage

More information

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai. Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,

More information

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Diabetes Management Coutts S, Wein T (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2014 Heart and Stroke Foundation November 2014

More information

Hypertension Management in Diabetic Patients

Hypertension Management in Diabetic Patients Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,

More information

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,

More information

Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus

Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus 1 Dissertation Title Page: Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus Qian Shi, MPH, PhD candidate Department of Global Health Management

More information

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei

More information

ADVANCE Endpoints. Primary outcome. Secondary outcomes

ADVANCE Endpoints. Primary outcome. Secondary outcomes ADVANCE Trial-NEJM 11,140 type 2 patients with h/o microvascular or macrovascular disease or 1 vascular disease risk factor Control A1c to 6.5% vs standard tx Intensive arm received gliclazide XL 30 to

More information

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80

More information

Treatment to reduce cardiovascular risk: multifactorial management

Treatment to reduce cardiovascular risk: multifactorial management Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University

More information

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes

More information

Review. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction

Review. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular

More information

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?

FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

Diabetes new challenges, new agents, new order

Diabetes new challenges, new agents, new order Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating

More information

UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC

UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC DISCLOSURES: I have no conflict-of-interest disclosures UPDATES: THE STRUGGLE

More information

Terapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci

Terapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,

More information

Hanyang University Guri Hospital Chang Beom Lee

Hanyang University Guri Hospital Chang Beom Lee Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit

More information

LATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?

LATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines? LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating

More information

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain) Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

Diabetic Management of the Cardiac Patient

Diabetic Management of the Cardiac Patient Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:

More information